TY - JOUR
T1 - Safety and tolerability of allogeneic dendritic cell vaccination with induction of Wilms tumor 1-specific T cells in a pediatric donor and pediatric patient with relapsed leukemia
T2 - A case report and review of the literature
AU - Saito, Shoji
AU - Yanagisawa, Ryu
AU - Yoshikawa, Kentaro
AU - Higuchi, Yumiko
AU - Koya, Terutsugu
AU - Yoshizawa, Kiyoshi
AU - Tanaka, Miyuki
AU - Sakashita, Kazuo
AU - Kobayashi, Takashi
AU - Kurata, Takashi
AU - Hirabayashi, Koichi
AU - Nakazawa, Yozo
AU - Shiohara, Masaaki
AU - Yonemitsu, Yoshikazu
AU - Okamoto, Masato
AU - Sugiyama, Haruo
AU - Koike, Kenichi
AU - Shimodaira, Shigetaka
N1 - Funding Information:
We wish to thank nurse Kayo Horiuchi for taking care of the patients and harvesting the PBMCs from the HSCT donor. This clinical trial was supported by Management Expense Grants from the Ministry of Education, Culture, Sports, Science and Technology, Japan (grant number: 24501330 and 24791050).
Publisher Copyright:
© 2015 International Society for Cellular Therapy.
PY - 2015/3/1
Y1 - 2015/3/1
N2 - A 15-year-old girl with acute lymphoblastic leukemia received allogeneic dendritic cell vaccination, pulsed with Wilms tumor 1 (WT1) peptide, after her third hematopoietic stem cell transplantation (HSCT). The vaccines were generated from the third HSCT donor, who was her younger sister, age 12 years. The patient received 14 vaccines and had no graft-versus-host disease or systemic adverse effect, aside from grade 2 skin reaction at the injection site. WT1-specific immune responses were detected after vaccination by both WT1-tetramer analysis and enzyme-linked immunosorbent spot assay. This strategy may be safe, tolerable and even feasible for patients with a relapse after HSCT.
AB - A 15-year-old girl with acute lymphoblastic leukemia received allogeneic dendritic cell vaccination, pulsed with Wilms tumor 1 (WT1) peptide, after her third hematopoietic stem cell transplantation (HSCT). The vaccines were generated from the third HSCT donor, who was her younger sister, age 12 years. The patient received 14 vaccines and had no graft-versus-host disease or systemic adverse effect, aside from grade 2 skin reaction at the injection site. WT1-specific immune responses were detected after vaccination by both WT1-tetramer analysis and enzyme-linked immunosorbent spot assay. This strategy may be safe, tolerable and even feasible for patients with a relapse after HSCT.
UR - http://www.scopus.com/inward/record.url?scp=84924958796&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84924958796&partnerID=8YFLogxK
U2 - 10.1016/j.jcyt.2014.10.003
DO - 10.1016/j.jcyt.2014.10.003
M3 - Article
C2 - 25484308
AN - SCOPUS:84924958796
SN - 1465-3249
VL - 17
SP - 330
EP - 335
JO - Cytotherapy
JF - Cytotherapy
IS - 3
ER -
